February 3, 2010
FY2009 Full Year Consolidated Financial Overview
Financial Highlight
Consolidated Statements of Income
(millions of yen, amounts of less than one million yen are omitted)
| Revenues | Cost of sales | SG&A expenses | (R&D expenses) | Operating Income |
|---|---|---|---|---|
| 428,947 | 192,851 | 153,482 | 55,315 | 82,612 |
| Operating Income to Sales Ratio (%) | Recurring Profit | Income before income taxes and minority interests | Net Income | Net Income per Share (Yen) |
|---|---|---|---|---|
| 19.3 | 90,395 | 89,416 | 56,634 | 104.00 |
Consolidated Balance Sheets
(millions of yen, amounts of less than one million yen are omitted)
| Total assets | Total current assets | Total fixed assets | Total current liabilities | Total fixed liabilities |
|---|---|---|---|---|
| 540,549 | 411,302 | 129,246 | 100,482 | 5,380 |
| Total shareholders' equity | Capital expenditure | Shareholders' Equity to Total Assets (%) | Annual dividend per share (yen) | Interim dividend per share (yen) |
|---|---|---|---|---|
| 437,492 | 14,649 | 80.0 | 40.00 | 17.00 |
Significant increase in both Revenues and Profits (Year on Year)*
Revenues: +31.2%, Sales excluding Tamiflu®: +9.4%
Solid domestic sales
Oncology: 20.9% increase in sales (#1 share in the domestic market: 17.3%*)
Bone and joint disease: 15.2% increase in sales
Transplant, Immunology and Infectious diseases: 9.2% increase in sales
Renal disease: 0.5% decrease in sales
Overseas sales: Stable despite the impact of strong yen
Jan-Dec 2009 Sales excluding Tamiflu®
*The scope of the market is defined by Chugai
and its share is calculated based on IMS Data.
"Copyright IMS Japan KK, 2010
Dec. 2009 YTD
Reprinted with permission"
and its share is calculated based on IMS Data.
"Copyright IMS Japan KK, 2010
Dec. 2009 YTD
Reprinted with permission"
Operating Income: +60.1%
Gross Profit: +18.1% due to increase in Revenues
SG&A expenses: +3.5%
Factors of change in Operating Income
Recurring Profit: +57.8% , Net Income: +44.0%
Accelerated by 2.1 billion yen non-operating income from exchange forward contract etc.
*Amounts are rounded to the nearest 0.1 billion yen.
Variance and % are calculated based on amounts shown.
Variance and % are calculated based on amounts shown.
More Information
268KB]
To view PDF files,
you will need Adobe® Reader® which is available as a free download.
